Literature DB >> 7426313

Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro.

H Eichholtz-Wirth.   

Abstract

The surviving fraction (SF) of Chinese hamster cells and HeLa cells after treatment with a range of Adriamycin concentrations and exposure times was determined. The cytostatic effect was proportional to the product of extracellular drug concentration (c) and exposure time (t) according to the equation: SF=e-ktc. By determining the intracellular drug concentration at various exposures, it could be shown that absorbed dose is not proportional to exposure dose.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7426313      PMCID： PMC2010346          DOI： 10.1038/bjc.1980.165

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

3.  A fluorometric assay for daunomycin and adriamycin in animal tissues.

Authors:  H S Schwartz
Journal:  Biochem Med       Date:  1973-06

4.  Survival kinetics of cultured human lymphoma cells exposed to adriamycin.

Authors:  B Drewinko; J A Gottlieb
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

5.  Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

Authors:  R S Benjamin; P H Wiernik; N R Bachur
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

6.  Survival and cell kinetics effects of adriamycin on mammalian cells.

Authors:  S C Barranco; E W Gerner; K H Burk; R M Humphrey
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

7.  Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.

Authors:  H E Skipper; F M Schabel; L B Mellett; J A Montgomery; L J Wilkoff; H H Lloyd; R W Brockman
Journal:  Cancer Chemother Rep       Date:  1970-12

8.  Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems.

Authors:  P R Twentyman
Journal:  Cancer Treat Rep       Date:  1976-12

9.  The concept of drug dose for in vitro studies with chemotherapeutic agents.

Authors:  K T Wheeler; V A Levin; D F Deen
Journal:  Radiat Res       Date:  1978-12       Impact factor: 2.841

10.  Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.

Authors:  M A Pacciarini; B Barbieri; T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Cancer Treat Rep       Date:  1978-05
View more
  22 in total

1.  Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.

Authors:  M C Walker; J R Masters; C N Parris; P J Hepburn; P J English
Journal:  Urol Res       Date:  1986

2.  A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

Authors:  P Jakobsen; L Bastholt; M Dalmark; P Pfeiffer; D Petersen; S B Gjedde; E Sandberg; C Rose; O S Nielsen; H T Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

4.  Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization.

Authors:  Jonathan K Pokorski; Kurt Breitenkamp; Lars O Liepold; Shefah Qazi; M G Finn
Journal:  J Am Chem Soc       Date:  2011-05-31       Impact factor: 15.419

Review 5.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

Authors:  A Haldane; G J Finlay; J B Gavin; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.